29
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Quantitative and Functional Analyses of Spleen and in Situ Islet Immune Cells Before and After Diabetes Onset in the Nod Mouse

, , , , , & show all
Pages 95-102 | Received 18 Sep 1991, Accepted 05 Dec 1991, Published online: 07 Jul 2009
 

Abstract

Cytofluorometric analysis using specific monoclonal antibodies directed against the T cell antigens Thy-1.2, CD4, CD8, CD4V/J(8.1+8.2+8.3), and the antigen Mac-1 expressed by mature macrophages and NK cells were used to characterize and quantify the phenotypes of (1) unfractionated and Percoll gradient fractionated in situ islet immune cells isolated from prediabetic and diabetic female NOD mouse spleens. We found in prediabetic female mice that the majority (-70%) of the in situ islet immune cells were Thy-1.2 positive T cells. CD4 positive T cells (-40%) were the most abundant phenotype together with double negative T cells (-20%). The percentages of CD8 positive T cells were -10%, and only -4% of the immune cells were Mac-1 positive. The percentages of CD4V/3(8.1+8.2+8.3) positive and double negative T cells in diabetic spleens were significantly higher in comparison to prediabetic spleens. In C57B1/6J control nondiabetic mice the percentage of double negative T cells in the spleens was significantly 4-fold lower when compared to diabetic NOD spleens. The specific cytolytic activity mediated by in situ islet immune cells against 51Cr-labeled dispersed syngeneic single-cell islet cells at an effector to target ratio of 20 was twenty- to thirty-fold higher than that mediated by prediabetic splenic lymphoid cells. It is concluded that prediabetic NOD mouse in situ islet immune cells are mostly CD4 positive and double negative T cells, and that CD4 and CD8 positive T cells in the intra-islet infiltrate warrants further evaluation as potential effector T cells in target J-cell destruction.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.